ReviewMolecular brain2018
Early Life Stress, Depression And Parkinson's Disease: A New Approach.
Review in Molecular brain, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 2 syntheses or guidelines pooled it, 115 citations in OpenAlex.
- Pooled it
- Neuroinflammation in Parkinson's Disease: From Gene to Clinic: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Stress and Parkinson's disease: from dysfunctional detection to impaired handling: a narrative review.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Evaluating the Relationship Between Early Non-Motor Symptoms and Late Diagnosis of Parkinson's Disease Based on the PPMI Database From 2012 to 2018: A Retrospective Cross-Sectional Study.Health science reports · 2026Article
- Perspective: Depression in Persons with Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2026Review
- From Stress to Neurodegeneration: A New Look at the Pathogenesis of Parkinson's Disease.Biomedicines · 2026Review
- Protective effect of formononetin in chronic unpredictable stress (CUS) linked to parkinson disease.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- A unifying theory of brain signaling and its possible role in acquired chronic disease.Frontiers in neuroscience · 2026Article
- Adverse experiences in childhood and young adulthood, genetic susceptibility, and neurodegenerative disease incidence: a lifespan analysis.European journal of psychotraumatology · 2025Article
- Impact of brief maternal separation on rodent models of anergia induced by dopamine depletion: analysis in mice of both sexes during adulthood.Psychopharmacology · 2025Article
- Use of Common Psychiatric Medications and Risk and Prognosis of Amyotrophic Lateral Sclerosis.JAMA network open · 2025Article
- The reduction in locomotor activity induced by restraint stress in young male mice involves the downregulation of hippocampal serotonergic and dopaminergic markers.IBRO neuroscience reports · 2025Article
- Stress exposure affects amyotrophic lateral sclerosis pathogenesis via PI3K/Akt and focal adhesion pathways: evidence from three experimental models.Scientific reports · 2025Article
- Relationship Between Depression and Neurodegeneration: Risk Factor, Prodrome, Consequence, or Something Else? A Scoping Review.Biomedicines · 2025Review
- Association between family poverty income ratio and Parkinson's disease in adults aged 40 and older: a study from NHANES 2003-2020.Frontiers in neurology · 2025Article
- Article
- The Interplay of Stress, Inflammation, and Metabolic Factors in the Course of Parkinson's Disease.International journal of molecular sciences · 2024Review
- Early Life Stress and Major Depressive Disorder-An Update on Molecular Mechanisms and Synaptic Impairments.Molecular neurobiology · 2024Review
- Neonatal stress disrupts the glymphatic system development and increases the susceptibility to Parkinson's disease in later life.CNS neuroscience & therapeutics · 2024Article
- Neurotensin and Neurotensin Receptors in Stress-related Disorders: Pathophysiology & Novel Drug Targets.Current neuropharmacology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review aims to shed light on the relationship that involves exposure to early life stress, depression and Parkinson's disease (PD). A systematic literature search was conducted in Pubmed, MEDLINE, EBSCOHost and Google Scholar and relevant data were submitted to a meta-analysis . Early life stress may contribute to the development of depression and patients with depression are at risk of developing PD later in life. Depression is a common non-motor symptom preceding motor symptoms in PD. Stimulation of regions contiguous to the substantia nigra as well as dopamine (DA) agonists have been shown to be able to attenuate depression. Therefore, since PD causes depletion of dopaminergic neurons in the substantia nigra, depression, rather than being just a simple mood disorder, may be part of the pathophysiological process that leads to PD. It is plausible that the mesocortical and mesolimbic dopaminergic pathways that mediate mood, emotion, and/or cognitive function may also play a key role in depression associated with PD. Here, we propose that a medication designed to address a deficiency in serotonin is more likely to influence motor symptoms of PD associated with depression. This review highlights the effects of an antidepressant, Fluvoxamine maleate, in an animal model that combines depressive-like symptoms and Parkinsonism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.